POST Online Media Lite Edition


Pfizer Q2 adjusted EPS up 21%

Staff Writer |
Pfizer reported second-quarter adjusted EPS of $0.81, an increase of 21% from previous year.

Article continues below

Adjusted income was up 19% year-over-year to $4.83 billion. For the second-quarter, reported net income increased 26% to $3.87 billion. EPS was $0.65 compared to $0.51.

Second-quarter revenues were $13.5 billion, an increase of 4%, compared to the prior-year quarter, reflecting the favorable impact of foreign exchange of 3%, and operational growth of 2%.

Innovative Health revenues increased 5% operationally in second-quarter 2018 to $8.27 billion, primarily driven by continued growth from key brands including Eliquis, Ibrance and Xeljanz globally, Prevnar 13/Prevenar 13 primarily in emerging markets and the U.S., as well as Xtandi in the U.S.

Operational revenue growth for Eliquis, Ibrance, Xeljanz and Xtandi was 42%, 19%, 37% and 21%, respectively.

Global Prevnar 13/Prevenar 13 revenues increased 7% operationally in second-quarter 2018. Second-quarter Essential Health revenues declined 4% operationally to $5.19 billion.

What to read next

Pfizer updates guidance, expects diluted EPS to be $1.29-$1.38
Pfizer Q1 net income increased year-over-year
Pfizer Q3 reported revenues decreased $274 million